» Articles » PMID: 7859740

The Dihedral Symmetry of the P53 Tetramerization Domain Mandates a Conformational Switch Upon DNA Binding

Overview
Journal EMBO J
Date 1995 Feb 1
PMID 7859740
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

The p53 tumor suppressor forms stable tetramers, whose DNA binding activity is allosterically regulated. The tetramerization domain is contained within the C-terminus (residues 323-355) and its three-dimensional structure exhibits dihedral symmetry, such that a p53 tetramer can be considered a dimer of dimers. Under conditions where monomeric p53 fails to bind DNA, we studied the effects of p53 C-terminal mutations on DNA binding. Residues 322-355 were sufficient to drive DNA binding of p53 as a tetramer. Within this region residues predicted by the three-dimensional structure to stabilize tetramerization, such as Arg337 and Phe341, were critical for DNA binding. Furthermore, substitution of Leu344 caused p53 to dissociate into DNA binding-competent dimers, consistent with the location of this residue at the dimer-dimer interface. The p53 DNA site contains two inverted repeats juxtaposed to a second pair of inverted repeats. Thus, the four repeats exhibit cyclic-translation symmetry and cannot be recognized simultaneously by four dihedrally symmetric p53 DNA binding domains. The discrepancy may be resolved by flexible linkers between the p53 DNA binding and tetramerization domains. When these linkers were deleted p53 exhibited novel DNA binding properties consistent with an inability to recognize four contiguous DNA repeats. Allosteric regulation of p53 DNA binding may involve repositioning the DNA binding domains from a dihedrally symmetric state to a DNA-bound asymmetric state.

Citing Articles

Characterization on the oncogenic effect of the missense mutations of p53 via machine learning.

Pan Q, Portelli S, Nguyen T, Ascher D Brief Bioinform. 2023; 25(1).

PMID: 38018912 PMC: 10685404. DOI: 10.1093/bib/bbad428.


Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.

Annor G, Elshabassy N, Lundine D, Conde D, Xiao G, Ellison V Front Cell Dev Biol. 2021; 9:772315.

PMID: 34881245 PMC: 8645790. DOI: 10.3389/fcell.2021.772315.


A phosphorylation-dependent switch in the disordered p53 transactivation domain regulates DNA binding.

Sun X, Dyson H, Wright P Proc Natl Acad Sci U S A. 2021; 118(1).

PMID: 33443163 PMC: 7817127. DOI: 10.1073/pnas.2021456118.


Roles of p53 Family Structure and Function in Non-Canonical Response Element Binding and Activation.

Cai B, Chao C, Huang H, Lee H, Kannagi R, Chen J Int J Mol Sci. 2019; 20(15).

PMID: 31357595 PMC: 6696488. DOI: 10.3390/ijms20153681.


The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity.

Thatte J, Massimi P, Thomas M, Boon S, Banks L J Virol. 2018; 92(16).

PMID: 29848585 PMC: 6069177. DOI: 10.1128/JVI.00465-18.


References
1.
Wade-Evans A, Jenkins J . Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J. 1985; 4(3):699-706. PMC: 554245. DOI: 10.1002/j.1460-2075.1985.tb03686.x. View

2.
Pavletich N, Chambers K, Pabo C . The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993; 7(12B):2556-64. DOI: 10.1101/gad.7.12b.2556. View

3.
Hope I, Struhl K . GCN4, a eukaryotic transcriptional activator protein, binds as a dimer to target DNA. EMBO J. 1987; 6(9):2781-4. PMC: 553703. DOI: 10.1002/j.1460-2075.1987.tb02573.x. View

4.
Landschulz W, Johnson P, McKnight S . The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science. 1988; 240(4860):1759-64. DOI: 10.1126/science.3289117. View

5.
Kraiss S, Quaiser A, Oren M, Montenarh M . Oligomerization of oncoprotein p53. J Virol. 1988; 62(12):4737-44. PMC: 253589. DOI: 10.1128/JVI.62.12.4737-4744.1988. View